ASC30
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
Ascletis Pharma (China) Co · Phase 2 · Completed · Enrollment 125
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Cohort 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 4 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 5 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 6 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Cohort 7 | Obesity or overweight | n/r | n/r | n/r | n/r |